Bone marrow disease biotech Imago BioSciences sets terms for $105 million IPO

Imago BioSciences, a Phase 2 biotech developing small molecules for bone marrow cancer and diseases, announced terms for its IPO on Monday.The South San Francisco, CA-based company plans to raise $105 million by offering 7 million shares at a price range of $14 to $16. The companRead More